GlassScriptPhysician profile
Carlysle Barfield
NPI 1053358440
$3,376.21
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,425 · 2020: $567 · 2021: $1,337 · 2022: $46.80.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $994.64 | 2019-2021 | |
| Pfizer INC. | $519.69 | 2019-2021 | |
| Abbvie INC. | $446.23 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $309.19 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $273.38 | 2019-2021 | |
| Lilly USA, LLC | $237.07 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $156.59 | 2019 | |
| Mallinckrodt Enterprises LLC | $142.28 | 2019 | |
| Mallinckrodt Hospital Products INC. | $118.27 | 2020-2021 | |
| Genentech USA, INC. | $81.47 | 2019 | |
| Janssen Biotech, INC. | $78.51 | 2021-2022 | |
| Horizon Therapeutics Plc | $18.89 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlysle Barfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.